http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. </p><p> A live audio webcast of the call, along with accompanying slides, will be available under "Events &amp; Presentations" in the Investor section of the Company's website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;esheet=54573884&amp;newsitemid=20260723238516&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;index=1&amp;md5=9e09b73c4d4e5f045acadcc0ea6a4e06" shape="rect">https://investor.verastem.com/events</a>. A replay of the webcast will be archived and available following the event. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html Thu, 23 Jul 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. </p><p> A live audio webcast of the call, along with accompanying slides, will be available under "Events &amp; Presentations" in the Investor section of the Company's website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;esheet=54573884&amp;newsitemid=20260723238516&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;index=1&amp;md5=9e09b73c4d4e5f045acadcc0ea6a4e06" shape="rect">https://investor.verastem.com/events</a>. A replay of the webcast will be archived and available following the event. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html Thu, 23 Jul 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. </p><p> A live audio webcast of the call, along with accompanying slides, will be available under "Events &amp; Presentations" in the Investor section of the Company's website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;esheet=54573884&amp;newsitemid=20260723238516&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;index=1&amp;md5=9e09b73c4d4e5f045acadcc0ea6a4e06" shape="rect">https://investor.verastem.com/events</a>. A replay of the webcast will be archived and available following the event. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html Thu, 23 Jul 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. </p><p> A live audio webcast of the call, along with accompanying slides, will be available under "Events &amp; Presentations" in the Investor section of the Company's website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;esheet=54573884&amp;newsitemid=20260723238516&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.verastem.com%2Fevents&amp;index=1&amp;md5=9e09b73c4d4e5f045acadcc0ea6a4e06" shape="rect">https://investor.verastem.com/events</a>. A replay of the webcast will be archived and available following the event. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Report+Second+Quarter+2026+Financial+Results+on+August+6%2C+2026/26804588.html Thu, 23 Jul 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html <p>Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC).</p> <p>TARGET-D 202 is a global, open-label trial evaluating VS-7375 monotherapy at 900 mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated NSCLC whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy. The trial includes a cohort for NSCLC patients with asymptomatic untreated brain metastases.</p> <p>The trial is the second registration-directed Phase 2 study underway for VS-7375, following http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html Wed, 22 Jul 2026 16:01:17 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html <p>Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC).</p> <p>TARGET-D 202 is a global, open-label trial evaluating VS-7375 monotherapy at 900 mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated NSCLC whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy. The trial includes a cohort for NSCLC patients with asymptomatic untreated brain metastases.</p> <p>The trial is the second registration-directed Phase 2 study underway for VS-7375, following http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html Wed, 22 Jul 2026 16:01:17 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html <p>Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC).</p> <p>TARGET-D 202 is a global, open-label trial evaluating VS-7375 monotherapy at 900 mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated NSCLC whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy. The trial includes a cohort for NSCLC patients with asymptomatic untreated brain metastases.</p> <p>The trial is the second registration-directed Phase 2 study underway for VS-7375, following http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html Wed, 22 Jul 2026 16:01:17 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html <p>Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC).</p> <p>TARGET-D 202 is a global, open-label trial evaluating VS-7375 monotherapy at 900 mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated NSCLC whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy. The trial includes a cohort for NSCLC patients with asymptomatic untreated brain metastases.</p> <p>The trial is the second registration-directed Phase 2 study underway for VS-7375, following http://www.streetinsider.com/FDA/Verastem+doses+first+patient+in+lung+cancer+trial+for+VS-7375/26801500.html Wed, 22 Jul 2026 16:01:17 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html <p class="bwalignc"> <i>TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer</i> </p><p class="bwalignc"> <i>A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases</i> </p><p class="bwalignc"> <i>Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Doses+First+Patient+in+TARGET-D+202+Phase+2+Registration-Directed+Trial+of+VS-7375+for+KRAS+G12D-Mutated+Advanced+Non-Small+Cell+Lung+Cancer/26801488.html Wed, 22 Jul 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Polar+Capital+Holdings+Plc/26745528.html si-local-file:///var/storage/secattach/20260708/26745528.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Polar+Capital+Holdings+Plc/26745528.html Wed, 08 Jul 2026 09:49:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Polar+Capital+Holdings+Plc/26745528.html si-local-file:///var/storage/secattach/20260708/26745528.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Polar+Capital+Holdings+Plc/26745528.html Wed, 08 Jul 2026 09:49:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Analyst+PT+Change/Verastem+%28VSTM%29+PT+Lowered+to+%2414+at+RBC+Capital/26738774.html RBC Capital analyst Leonid Timashev lowered the price target on Verastem (NASDAQ: VSTM) to $14.00 (from $15.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Verastem+%28VSTM%29+PT+Lowered+to+%2414+at+RBC+Capital/26738774.html Tue, 07 Jul 2026 08:00:26 -0400 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html Thu, 02 Jul 2026 16:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html Thu, 02 Jul 2026 16:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html Thu, 02 Jul 2026 16:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). </p><p> The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26728345.html Thu, 02 Jul 2026 16:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26692212.html si-local-file:///var/storage/secattach/20260625/26692212.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26692212.html Thu, 25 Jun 2026 16:02:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26692212.html si-local-file:///var/storage/secattach/20260625/26692212.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26692212.html Thu, 25 Jun 2026 16:02:00 -0400 O.12496614 VSTM